Cumberland Pharmaceuticals
Dr. Bernard served as their Medical Director from 1999 until 2010 and currently serves as Chair of their Medical Advisory Board. He has served on their board of directors since 2010. Dr. Bernard is the Executive Vice President for Research at Vanderbilt University Medical Center, and also the Melinda Owen Bass Professor of Medicine and former Chief of the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt. In addition, he is Executive Vice President for Research, Senior Associate Dean for Clinical Sciences and Chairman of Vanderbilt’s Pharmacy and Therapeutics Committee, which is responsible for approving the Vanderbilt Medical Center Formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980 and he has been steering committee chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994 through its conclusion in 2014. This network is the only federally supported ongoing system for the conduct of research in the hospital Intensive Care Unit, or ICU. He holds a B.S. from the University of Southwestern Louisiana and an M.D. from Louisiana State University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Cumberland Pharmaceuticals
2 followers
Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. With a focus on underserved niche markets, including hospital acute care and gastroenterology, they deliver products that serve patients in the U.S. market. Cumberland also makes its products available to patients internationally through select strategic partnerships. They own the worldwide rights to all their brands. While Cumberland’s commercial capabilities are focused on the U.S. market, their business development team is actively pursuing opportunities to make their brands available to patients in markets around the globe. Their primary mission is to improve upon patient care with products that offer clear advantages over existing treatments. They also strive to deliver solutions that may help reduce costs for healthcare providers and, ultimately, patients.